Skip to content

Developing small molecule FPR agonists to treat infectious diseases and combat the growing threat of resistant bacterial infections

Antibiotic-resistant infections are becoming a global health threat

As traditional antibiotics become less effective and common infections increasingly challenging to treat, new approaches are critical. By developing novel anti-infective compounds, Inicure is targeting a wide range of infectious diseases, addressing a global health threat and a substantial and growing market.

Pyelonephritis (UPEC) caused by severe complications of UTIs may lead to kidney damage and death—growing incidence due to antibiotic resistance and an estimated global market size of €200 million.

Chronic wound infections are challenging and costly, worsening with rising antibiotic resistance—estimated global market size: €1.2 billion.

MRSA infections are becoming untreatable with current antibiotics, causing up to 40,000 deaths globally each year—estimated global market size: €3.9 billion.

Inicure is developing patent-protected compounds acting as potent agonists of the formyl peptide receptor-1 (FPR1)

Our compounds show potent anti-infective effects in preclinical infection models, including E. coli UTIs and Multi Resistant Staphylococcus Aureus (MRSA) infections, without causing toxicity.